Australian Securities Exchange-listed owner of the “13 Seeds” and “8 Seeds” range of health and wellness products, Live Verdure, has started selling its “13 Seeds” hemp seed oil capsules on Amazon’s US platform.
“Live Verdure is thrilled to now have our products approved for sale in two Amazon Marketplace regions,” said managing director, Ran Vaingold. “This paves the way for Live Verdure to quickly and easily bring our customers more products in the future.”
The move follows the company’s recent announcement that it had successfully registered 13 Seeds with the US Food and Drug Administration for sale of its hemp-based products in the US. Live Verdure chose the US as its first international market due to it being the largest consumer of nutraceuticals globally, with access to Amazon’s reach a major development for the company. Of the US$386b revenue Amazon made in 2020, more than 50 per cent came from its online marketplace product sales, predominantly from the US Marketplace. Live Verdure already sells via Amazon in Australia.
“We are confident Amazon’s exceptional customer service and delivery times will enhance LV1’s product reach, bringing us closer to our goal of having 13 Seeds products in all health and wellness conscious households worldwide,” Mr Vaingold said.
In the US, Live Verdure’s approach with Amazon will see it tap the tech giant’s complimentary advanced order fulfilment network and services, including 24/7 customer support, payment processing and fraud protection, packing and delivery. Live Verdure will maintain control over the pricing and marketing of its products.
The company said selling on both Amazon US and Australia will increase brand discovery of its products, as Amazon US is not only a retailer but also one of the world’s leading product discovery platforms.
Started in Melbourne in 2016 as a plant-based food, nutraceutical and skincare company, Live Verdure owns the two rapidly-growing hemp consumer brands, “13 Seeds” and “8 Seeds” using 100 per cent Tasmanian hemp.
Sales were US$145,000 in the quarter ended 31 March 2021, up 6 per cent year-on-year, and the company sees substantial growth for the nutraceutical industry, based on increased global concern for health and wellness, especially in the aftermath of the COVID-19 pandemic.